Benitec Biopharma Inc.
BNTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001808898
No open-market purchases or sales by Benitec Biopharma Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q2 2026, worth $463.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Benitec Biopharma Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Benitec Biopharma Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Buchi J Kevin | Director | 52,097 | Jun 30, 2026 | 2 |
| Friedman David Matthew | Director | – | May 28, 2026 | 1 |
| Mates Sharon | Director | – | Jan 26, 2026 | 3 |
| Montanova Capital, LLC | Director, 10% Owner | 1,848,156Indirect | Dec 29, 2025 | 3 |
| Cowen Aaron | 10% Owner | 1,848,156Indirect | Dec 29, 2025 | 3 |
| Averill Master Fund, Ltd. | Director, 10% Owner | 1,848,156Indirect | Dec 29, 2025 | 3 |
| Averill Madison Master Fund, Ltd. | Director, 10% Owner | 1,848,156Indirect | Dec 29, 2025 | 3 |
| Smith Edward F | Director | – | Dec 3, 2025 | 1 |
| Francis Peter | Director | – | Dec 3, 2025 | 1 |
| Mehta Kishan | Director | – | Dec 3, 2025 | 1 |
| Boston Megan | Chief Financial Officer | 25,907 | Nov 20, 2025 | 1 |
| Banks Jerel A. | Chief Executive Officer | – | Nov 20, 2025 | 1 |
| Mukadam Sophie | Chief Operating Officer | – | Nov 20, 2025 | 1 |
| Oliveira Steven Michael | 10% Owner | 1,000,000Indirect | Dec 9, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 29, 2025 (view filing)7:31 PM ET | Dec 23-29 | 6 days | Montanova Capital, LLC and 3 othersDirector, 10% Owner | PPurchaseCommon stock, par value $0.0001 per share | +144.2K | $13.20 | +$1.90M | +8.5%1.85M after | 6 lots |
| Dec 22, 2025 (view filing)7:45 PM ET | Dec 18-22 | 4 days | Montanova Capital, LLC and 3 othersDirector, 10% Owner | PPurchaseCommon stock, par value $0.0001 per share | +46.1K | $11.68 | +$539.0K | +2.6%1.83M after | 6 lots |
| Nov 10, 2025 (view filing)9:51 PM ET | Nov 7 | 3 days | Montanova Capital, LLC and 3 othersDirector, 10% Owner | PPurchaseCommon stock, par value $0.0001 per share | +1.48M | $13.50 | +$20.0M | +437.9%1.82M after | 2 lots |
| Apr 2, 2025 (view filing)4:37 PM ET | Mar 31 | 2 days | Montanova Capital, LLC and 3 othersDirector, 10% Owner | PPurchaseCommon stock, par value $0.0001 per share | +16.5K | $12.83 | +$211.7K | +1.6%1.07M after | 4 lots |
| Mar 28, 2025 (view filing)4:51 PM ET | Mar 26 | 2 days | Montanova Capital, LLC and 3 othersDirector, 10% Owner | PPurchaseCommon stock, par value $0.0001 per share | +900.0K | $13.00 | +$11.7M | +539.7%1.07M after | 2 lots |
| Dec 26, 2024 (view filing)4:28 PM ET | Dec 23-24 | 3 days | Montanova Capital, LLC and 3 othersDirector, 10% Owner | PPurchaseCommon stock, par value $0.0001 per share | +47.5K | $11.09 | +$527.2K | +5.2%960.6K after | 4 lots |
| Dec 5, 2024 (view filing)4:36 PM ET | Dec 3 | 2 days | Montanova Capital, LLC and 3 othersDirector, 10% Owner | PPurchaseCommon stock, par value $0.0001 per share | +42.0K | $9.60 | +$403.2K | +4.6%955.1K after | 2 lots |
| Nov 21, 2024 (view filing)4:24 PM ET | Nov 19-20 | 2 days | Montanova Capital, LLC and 3 othersDirector, 10% Owner | PPurchaseCommon stock, par value $0.0001 per share | +41.4K | $10.05 | +$416.6K | +4.6%950.3K after | 4 lots |
| Aug 14, 2023 (view filing) | Aug 11 | 3 days | Buchi J KevinDirector | PPurchase | +51.8K | – | – | +18,244.0%52.1K after | |
| Aug 14, 2023 (view filing) | Aug 11 | 3 days | Buchi J KevinDirector | PPurchase | +51.8K | – | – | –51.8K after | Derivative |
| Aug 14, 2023 (view filing) | Aug 11 | 3 days | Boston MeganExecutive Director | PPurchase | +25.9K | – | – | New position25.9K after | |
| Aug 14, 2023 (view filing) | Aug 11 | 3 days | Boston MeganExecutive Director | PPurchase | +25.9K | – | – | –25.9K after | Derivative |
| Dec 9, 2021 (view filing) | Apr 28-Dec 9 | 225 daysLate | Oliveira Steven Michael10% Owner | PPurchaseCommon Stock, par value $0,0001 per share | +331.9K | $4.51 | +$1.50M | +49.7%1.00M after | 6 lots |